Overview: We are seeking a passionate and skilled Scientist to join our R&D team. In this role, you will lead efforts to integrate our molecular profiling platform (EpiRead) with our epigenetic editing technology (EpiWrite). You will spearhead the development of high-throughput genetic screening to functionally perturb genomic regions identified by EpiRead. Your work will generate critical datasets to develop predictive models that elucidate transcriptional regulation networks, guiding therapeutic interventions through epigenetic editing (EpiWrite) or other modalities.
Key Responsibilities:
- Develop and optimize lentiviral-based CRISPRa/i screens to assess the function of coding and non-coding regulatory regions.
- Design and execute validation studies in disease-relevant preclinical models.
- Innovate and implement new CRISPR screening formats as required.
- Contribute to the development of single-cell RNA-seq / ATAC-seq workflows.
- Maintain meticulous records of experiments, reagents, and samples.
- Analyze and interpret scientific data, preparing reports and presentations for internal and external stakeholders.
Required Qualifications:
- Ph.D. in Molecular Biology, Biochemistry, Biological Engineering, or a related field, or M.S. with 4+ years of relevant experience.
- At least 2 years of hands-on experience with CRISPR-based, high-throughput functional genomic screenings.
- Proficiency in key workflows, including mammalian cell culture, gRNA library design and cloning, lentiviral packaging and transduction, and NGS library preparation.
- Experience with single-cell workflows is highly desirable.
- Familiarity with gene editing, RNAi/ASO, mRNA-based therapy and delivery technologies is a plus.
Scientist I: The expected annual pay range for this position is $110,000 – $125,000.
Scientist II: The expected annual pay range for this position is $112,000 – $132,000.
Exact compensation and title may vary based on skills and years of experience.
Moonwalk Biosciences is pioneering a new class of precision epigenetic medicines. Its novel platform technology provides a complete view of the epigenome in health and disease, with the most advanced AI prediction of epigenetic targets, and the broadest set of epigenetic engineering tools. Moonwalk was Co-founded by Alex Aravanis, M.D., Ph.D., former CTO of Illumina, world-renowned scientist Feng Zhang, Ph.D. of the Broad Institute of MIT and Harvard, and a distinguished set of industry leaders and company builders. It has raised $57 million led by Alpha Wave Ventures, and joined by other leading life sciences investors ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures.